



## **Lumito – winner in the poster competition and awarded with a presentation at the Digital Pathology & AI Congress in London**

Lumito has been selected by the conference committee as the winner of the poster competition and has been awarded a 15 min presentation at the Digital Pathology & AI Congress in London on 5-6 December. Lumito will be presented to over 420 attendees and 35 exhibitors at the sold out meeting. Krzysztof Krawczyk, R&D Manager at Lumito, will hold the presentation “Up-Converting NanoParticles as a powerful tool for tissue evaluation” at 5.25-5.40 p m, Dec 5th.

"For decades hematoxylin and eosin (H&E) together with DAB chromogenic stain has been a standard way to visualize morphology of the cells and markers of interest. Staining kit and a novel device developed by Lumito give hope for more accurate diagnosis by keeping the advantage of H&E staining and combining it, in one image, with luminescent data, ideal for generating ground truth for machine learning algorithms", says Krzysztof Krawczyk.



### **For more information contact:**

Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, [sn@lumito.se](mailto:sn@lumito.se)

### **Lumito in brief**

Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito's IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents. Lumito's share Lumito and warrant Lumito TO2 are traded at the NGM Nordic MTF marketplace.